Suspected black cohosh hepatotoxicity: No evidence by meta-analysis of randomized controlled clinical trials for isopropanolic black cohosh extract

Menopause

Volumn 18, Issue 4, 2011, Pages 366-375

  Naser, Belal ^a   Schnitker, Jörg ^b   Minkin, Mary Jane ^c   De Arriba, Susana Garcia ^a   Nolte, Klaus Ulrich ^a   Osmers, Rüdiger ^d  

^a Schaper & Brummer GmbH & Co KG   (Germany)

^b Institute for Applied Statistics   (Germany)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Hildesheim Hospital GmbH   (Germany)

Author keywords

Black cohosh; Black cohosh hepatotoxicity; Liver function; Meta analysis

Indexed keywords

2 PROPANOL; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CIMICIFUGA RACEMOSA EXTRACT; GAMMA GLUTAMYLTRANSFERASE; PLACEBO;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CIMICIFUGA RACEMOSA; DRUG EFFICACY; DRUG SAFETY; HUMAN; LIVER FUNCTION; LIVER TOXICITY; MENOPAUSAL SYNDROME; META ANALYSIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARDIZATION; STATISTICAL SIGNIFICANCE; STATISTICS;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; CIMICIFUGA; DRUG-INDUCED LIVER INJURY; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HOT FLASHES; HUMANS; LIVER; LIVER FUNCTION TESTS; MENOPAUSE; MIDDLE AGED; PHYTOTHERAPY; PLANT EXTRACTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 79955026604     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181fcb2a6     Document Type: Article

References (76)

1. Shams T, Setia MS, Hemmings R, McCusker J, Sewitch M, Ciampi A. Efficacy of black cohoshYcontaining preparations on menopausal symptoms: a meta-analysis. Altern Ther Health Med 2010;16:36-44.
2. Whiting PW, Clouston A, Kerlin P. Black cohosh and other herbal remedies associated with acute hepatitis. Med J Aust 2002;177:432-435.
3. Lontos S, Jones RM, Angus PW, Gow PJ. Acute liver failure associated with the use of herbal preparations containing black cohosh. Med J Aust 2003;179:390-391. (Pubitemid 37265139)
4. O'Connor AM, Merel NH, Te HS, Cohen SM. A case of autoimmune hepatitis associated with the use of black cohosh. Am J Gastroenterol 2003;98:S165.
5. Cohen SM, O'Connor AM, Hart J, Merel NH, Te HS. Autoimmune hepatitis associated with the use of black cohosh: a case study. Menopause 2004;11:575-577. (Pubitemid 40362157)
6. Workshop on the Safety of Black Cohosh in Clinical Studies. National Center for Complementary and Alternative Medicine, NIH Office of Dietary Supplements, National Institutes of Health, Bethesda, MD. November 22, 2004. Available at: http://nccam.nih.gov/news/pastmeetings/blackcohosh-mtngsumm.pdf. Accessed January 2010.
7. Lynch CR, Folkers ME, Hutson WR. Fulminant hepatic failure associated with the use of black cohosh: a case report. Liver Transpl 2006; 12:989-992. (Pubitemid 43960376)
8. Levitsky J, Alli TA, Wisecarver J, Sorrell MF. Fulminant liver failure associated with the use of black cohosh. Dig Dis Sci 2005;50:538-539. (Pubitemid 40543744)
9. Betz JM, Anderson L, Avigan M, et al. Black cohoshVconsiderations of safety and benefit. Nutr Today 2009;44:155-162.
10. Naser B, Liske E. Placebo-controlled trial shows no effects of an isopropanolic black cohosh extract on liver function. The American College of Obstetricians and Gynecologists. Monday Posters 64. Available at: http://www.acog.org.acm/pdf/postersMon.pdf. Accessed February 2010.
11. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Metaanalyses. Lancet 1999;354:1896-1900.
12. Uebelhack R, Blohmer JU, Graubaum HJ, Busch R, Gruenwald J, Wernecke KD. Black cohosh and St. John's wort for climacteric complaints: a randomized trial. Obstet Gynecol 2006;107:247-255.
13. Liske E, Hänggi W, Henneicke-von Zepelin HH, Boblitz N, Wüstenberg P, Rahlfs VW. Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect. J Womens Health Gend Based Med 2002;11/2:163-174.
14. Bai W, Henneicke-von Zepelin HH, Wang S, et al. Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: a randomized, double blind, parallel-controlled study versus tibolone. Maturitas 2007; 58:31-41. (Pubitemid 47268705)
15. Osmers R, Friede M, Liske E, et al. Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. Obstet Gynecol 2005; 105:1074-1083. (Pubitemid 40571028)
16. Whitehead A. Metaanalysis of Controlled Clinical Trials. Chichester, England: John Wiley & Sons, Ltd., 2002.
17. Hedges LV, Olkin J. Statistical Methods for Meta-Analysis. Orlando, FL: Academic Press, 1985.
18. Nappi RE, Malavasi B, Brundu B, Facchinetti F. Efficacy of Cimicifuga racemosa on climacteric complaints: a randomised study versus low-dose transdermal estradiol. Gynecol Endocrinol 2005;20:30-35. (Pubitemid 40445238)
19. Wuttke W, Gorkow C, Seidlova-Wuttke D. Effects of black cohosh (Cimicifuga racemosa) on bone turnover, vaginal mucosa, and various blood parameters in postmenopausal women: a double-blind, placebocontrolled, and conjugated estrogensYcontrolled study. Menopause 2006; 13:185-196.
20. Frei-Kleiner S, Schaffner W, Rahlfs VW, et al. Cimicifuga racemosa dried ethanolic extract in menopausal disorders: a double-blind placebocontrolled clinical trial. Maturitas 2005;51:397-404. (Pubitemid 41019367)
21. Lopes CMC, Celestino CA, Hayashida SAY. The hepatic function in postmenopausal woman treated with a standardized dry extract of the roots and rhizome of Cimicifuga racemosa L. Rev Bras Med 2009; 66:254-259.
22. Geller SE, Shulman LP, van Breemen RB, et al. Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial. Menopause 2009;16:1156-1166.
23. Chung D-J, Kim H-Y, Park K-H, et al. Black cohosh and St. John's wort (GYNO-PlusA) for climacteric symptoms. Yonsei Med J 2007;48: 289-294. (Pubitemid 46711761)
24. Stoll W. Phytotherapeutikum beeinflusst atrophisches Vaginalepithel: Doppelblindversuch Cimicifuga vs. Oestrogenpräparat. Therapeutikon 1987;1:23-31.
25. Kaiser WD, Martin R, Schellenberg R, Schrader E, Saller R. Cimicifugaracemosa- Extrakt Ze 450 bei Wechseljahresbeschwerden-Eine pflanzliche, nichthormonale Alternative. Ars Medici 2008;17:771-774.
26. Newton KM, Reed SD, LaCroix AZ, Grothaus LC, Ehrlich K, Guiltinan J. Treatment of vasomotor symptoms of menopause with black cohosh, mutlibotanicals, soy, hormone therapy, or placebo. Ann Intern Med 2006; 145:869-879. (Pubitemid 351639962)
27. Düker EM, Kopanski L, Jarry H, Wuttke W. Effects of extracts from Cimicifuga racemosa on gonadotropin release in menopausal woman and ovariectomized rats. Planta Med 1991;57:399-510.
28. Oktem M, Eroglu D, Karahan HB, Taskintuna N, Kuscu E, Zeyneloglu HB. Black cohosh and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized trial. Adv Ther 2007;24:448-461. (Pubitemid 46988389)
29. Lehmann-Willenbrock E, Riedel H-H. Klinische und endokrinologische Untersuchungen zur Therapie ovarieller Ausfallserscheinungen nach Hysterektomie unter Belassung der Adnexe. Zentralbl Gynäkol 1988; 110:611-618.
30. Danan G, Benichou C. Causality assessment of adverse reactions to drugsVI. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-1330. (Pubitemid 23333873)
31. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugsVII. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993;46:1331-1336. (Pubitemid 23333874)
32. Teschke R. Hepatotoxicity by drugs and dietary supplements: safety perspectives on clinical and regulatory issues. Ann Hepatol 2009;8: 184-195.
33. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum, 1988.
34. Raus K, Brucker C, Gorkow C, Wuttke W. First-time proof of endometrial safety of the special black cohosh extract (Actaea or Cimicifuga racemosa extract) CR BNO 1055. Menopause 2006;13:678-691. (Pubitemid 44079538)
35. Nasr A, Nafeh H. Influence of black cohosh (Cimicifuga racemosa) use by postmenopausal women on total hepatic perfusion and liver functions. Fertil Steril 2009;92:1780-1782.
36. Van Breemen RB, Liang W, Banuvar S, et al. Pharmacokinetics of 23- Epi-26-deoxyactein in women after oral administration of a standardized extract of black cohosh. Clin Pharmacol Ther 2010;87:219-225.
37. Firenzuoli F, Gori L, Roberti di Sarsina P. Black cohosh hepatic safety: follow-up of 107 patients consuming a special Cimicifuga racemosa rhizome herbal extract and review of literature. eCAM Adv Access. 2008;1-7. Available at: http://ecam.oxfordjournals.org/cgi/reprint/nen009v1. Accessed September 2010.
38. Lüde S, Török M, Dieterle S, et al. Hepatic effects of Cimicifuga racemosa extract in vivo and in vitro. Cell Mol Life Sci 2007;64: 2848-2857. (Pubitemid 351152265)
39. Lüde S, Török M, Dieterle S, et al. Erratum to: Hepatic effects of Cimicifuga racemosa extract in vivo and in vitro. Cell Mol Life Sci 2010 DOI 10.1007/s00018-010.0310-1.
40. Mazzanti G, Di Sotto A, Franchitto A, et al. Effects of Cimicifuga racemosa extract on liver morphology and hepatic function indices. Phytomedicine 2008;15:1021-1024.
41. Huang Y, Jiang B, Nuntanakorn P, et al. Fukinolic acid derivatives and triterpene glycosides from black cohosh inhibit CYP isozymes, but are not cytotoxic to Hep-G2 cells in vitro. Curr Drug Saf 2010;5: 118-124.
42. Gurley BJ, Swain A, Hubbard MA, et al. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. Mol Nutr Food Res 2008;52:755-763.
43. Borrelli F, Ernst E. Black cohosh (Cimicifuga racemosa): a systematic review of adverse events. Am J Obstet Gynecol 2008;199:455-466.
44. European Medicines Agency, Committee on Herbal Medicinal Products (HMPC). Assessment of case reports connected to herbal medicinal products containing Cimicifugae racemosae rhizoma (black cohosh, root). London, England. May 8, 2007. Available at: http://www.emea.europa.eu/pdfs/human/hmpc/26925806en.pdf. Accessed January 2010.
45. Mahady GB, Low Dog T, Barrett ML, et al. United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity. Menopause 2008;15:628-638.
46. Health Canada. Fact sheet: black cohosh. Available at: http://www. hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/ cohosh-grappes-fact-fiche-eng.php. Accessed September 2010.
47. MHRA. Press release: MHRA action on safety concerns over black cohosh and liver injury. Available at: http://www.mhra.gov.uk/NewsCentre/Pressreleases/ CON2024116. Accessed September 2010.
48. TGA. Black cohosh (Cimicifuga racemosa). Available at: http://www. tga.gov.au/cm/0705blkcohosh.htm. Accessed September 2010.
49. Teschke R, Schwarzenboeck A. Suspected hepatotoxicity by Cimicifugae racemosae rhizoma (black cohosh, root): critical analysis and structured causality assessment. Phytomedicine 2009;16:72-84.
50. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30: 239-245. (Pubitemid 12149145)
51. Garcia-Cortez M, Lucena M, Pachkoria K, Borrazy Y, Hidalgo R, Andrade R. Evaluation of Naranjo Adverse Drug Reactions Probability Scale in causality assessment of drug-induced liver injury. Aliment Pharmacol Ther 2008;27:780-789. (Pubitemid 351490076)
52. Teschke R. A U.S. review determined that black cohosh products should be labelled with a cautionary statement [letter to the editor]. Menopause 2009;16:214.
53. Teschke R, Bahre R, Fuchs J, Schmidt-Taenzer W, Wolff A. Suspected black cohosh hepatotoxicity-causality assessment versus safety signal. Quality versus quantity [letter to the editor]. Maturitas 2009;64: 141-142.
54. Teschke R. Letter to the editor: in response. Menopause 2010;17:1089.
55. Chow ECY, Teo M, Ring JA, Chen JW. Liver failure associated with the use of black cohosh for menopausal symptoms. Med J Aust 2008;188: 420-422.
56. Nisbet BC, O'Connor RE. Black cohoshYinduced hepatitis. Del Med J 2007;79:441-444.
57. Joy D, Joy J, Duane P. Black cohosh: a cause of abnormal postmenopausal liver function tests. Climacteric 2008;11:84-88.
58. Vannacci A, Lapi F, Gallo E, et al. A case of hepatitis associated with long-term use of Cimicifuga racemosa. Altern Ther Health Med 2009;15: 62-63.
59. Van de Meerendonk HW, van Hunsel FP, van der Wiel HE. Autoimmunhepatitis door zilverkaars. Ned Tijdschr Geneeskd 2009;6: 246-249.
60. Guzman G, Kallwitz ER, Wojewoda C, et al. Liver injury with features mimicking autoimmune hepatitis following the use of black cohosh. Case Reports in Medicine. Article ID 918156. Hindawi Publishing Corporation, .2009. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2814377/pdf/CRM2009-918156.pdf. Accessed September 2010.
61. Pierard S, Coche JC, Lanthier P, et al. Severe hepatitis associated with the use of black cohosh: a report of two cases and an advice for caution. Eur J Gastroenterol Hepatol 2009;21:941-945.
62. Teschke R. Liver failure associated with the use of black cohosh for menopausal symptoms [letter to the editor]. Med J Aust 2009;190:99-100.
63. Naser B, Liske E. Liver failure associated with the use of black cohosh for menopausal symptoms [letter to the editor]. Med J Aust 2009; 190:99-100.
64. Teschke R, Bahre R, Fuchs J, Wolff A. Black cohosh hepatotoxicity: quantitative causality evaluation in nine suspected cases. Menopause 2009;16:956-965.
65. Naser B, Liske E. Adverse liver reactions to black cohosh: are they accurately reported? Climacteric 2008;11:114.
66. In The United States District Court for The District of Nebraska. Case: 8:05-cv-00066-LES-TDT. Document #: 149. Date filed 09/08/2006. Available at: http://www.ahpa.org/Portals/0/pdfs/06-0908-BlackCohosh- NebraskaDistrictCt.pdf. Accessed January 2010.
67. Levitsky J, Alli TA, Wisecarver J, Sorrell MF. Erratum: Fulminant liver failure associated with the use of black cohosh. Dig Dis Sci 2008;53:869.
68. Teschke R, Bahre R, Genthner A, Fuchs J, Schmidt-Taenzer W, Wolff A. Suspected black cohosh hepatotoxicityVchallenges and pitfalls of causality assessment. Maturitas 2009;63:302-314.
69. Teschke R. Black cohosh and suspected hepatotoxicity: inconsistencies, confounding variables, and prospective use of a diagnostic causality algorithm: a critical review. Menopause 2010;17:426-440.
70. Walker A, Cavanaugh RJ. The occurrence of new hepatic disorders in defined populations. Postmarketing Surveill 1992;6:107-117.
71. Shakil AO, Kramer D, Mazariegos GV, Fung JJ, Rakela J. Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl 2000;6:163-169. (Pubitemid 30173994)
72. Mason A, Sallie R. What causes fulminant hepatic failure of unknown etiology? Am J Clin Pathol 1995;104:491-494.
73. Van Breemen RB, Fong HH, Farnsworth NR. Ensuring the safety of botanical dietary supplements. Am J Clin Nutr 2008;87:509-513.
74. N.N Health Products and Food Branch. Marketed health products directorate. Canadian Adverse Reaction Newsletter Editorial Team. Available at: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei-v20n1-eng. php#a1t1. Accessed January 2010.
75. Low Dog T, Powell KL, Weisman SM. Critical evaluation of the safety of Cimicifuga racemosa in menopause symptom relief [review]. Menopause 2003;10:299-313. (Pubitemid 36870502)
76. The European Scientific Cooperative on Phytotherapy (ESCOP)- Monograph on Cimicifugae Rhizoma (Black Cohosh). In Press 2011. http://www.escop.com.